Previous studies have shown that lapatinib combined with paclitaxel significantly increases the overall response rate in patients with HER2‐positive GC, and in patients with HER2 FISH‐positive IHC 3+, the risk of disease progression and death is markedly lower with combination therapy than with paclitaxel alone.66 Here, ERBB2 is linked to gastric cancer.